2. Disease Areas
  3. Infection Urogenital Disease
  4. HIV Infection Sexually Transmitted Disease
  5. HIV-1 Infection

HIV-1 Infection

HIV-1 infection is caused by a spherical, enveloped, single-stranded positive-sense RNA retrovirus that integrates its reverse-transcribed DNA into the host genome, leading to progressive immunodeficiency and AIDS. HIV-1, the predominant strain responsible for the global AIDS pandemic, is classified into three groups (M, O, N), with group M driving the epidemic and further subdivided into multiple subtypes (A–K) and circulating recombinant forms (CRFs) arising from co-infection. While subtype B is prevalent in North America and Europe, non-B subtypes and CRFs now account for over 90% of global infections, with increasing prevalence in the U.S. due to globalization. Advances in sequencing, particularly next-generation sequencing (NGS), have enhanced surveillance, detection, viral load monitoring, drug-resistance testing, and understanding of viral diversity, quasispecies dynamics, and transmission patterns, supporting more effective clinical management and public health strategies.

HIV-1 Infection (61):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W020658
    L-α-Phosphatidylinositol 97281-52-2
    L-α-Phosphatidylinositol is a type of phospholipid. L-α-Phosphatidylinositol can serve as an antigen in ELISA assays for screening antiphospholipid antibodies. L-α-Phosphatidylinositol can be used in studies related to HIV-1 infection.
    L-α-Phosphatidylinositol
  • HY-160229
    ssRNA40 sodium 98.34%
    ssRNA40 sodium (R-1075 sodium) is a single-stranded RNA40 derived from HIV-1. ssRNA40 sodium activates the TLR7, TLR8, TLR2, RIG-I, MDA5, MyD88, Caspase-3, IRE1α, NLRP3 inflammasome and IRF7 signaling pathways. ssRNA40 sodium alters mRNA expression in neutrophils, induces pro-inflammatory cytokines, ROS, autophagy (autophagy), pyroptosis (pyroptosis), neuronal death, neurodegeneration, aggregate formation and NK cell activation. ssRNA40 sodium activates the expression of CD62L, CD11b, CD69, MX1, OAS1, ATG7, LC3B and XBP1 in immune cell and neuronal populations. ssRNA40 sodium causes cortical neuron loss and axonal damage in mice in a TLR7-dependent manner. ssRNA40 sodium can be used in research on HIV-1 infection, neurodegeneration, COVID-19 and HIV-associated neurological disorders.
    ssRNA40 sodium
  • HY-W037893
    CHMA1004 dihydrochloride 122323-88-0 99.38%
    CHMA1004 (Methyl piperazine-2-carboxylate; METTL3 activator-1) dihydrochloride is a METTL3/METTL14/WTAP methyltransferase complex activator. CHMA1004 dihydrochloride exhibits neuroprotective and anxiolytic potential by enhancing m6A methylation modification of RNA. CHMA1004 dihydrochloride promotes HIV replication in an infection context. CHMA1004 dihydrochloride can be used in studies related to anxiety disorders and HIV-1 infection.
    CHMA1004 dihydrochloride
  • HY-18257
    Rolitetracycline 751-97-3 ≥98.0%
    Rolitetracycline is a highly soluble, broad-spectrum antibiotic derived from tetracycline. Rolitetracycline binds to and stabilizes bovine serum albumin, and also inhibits HIV-1 integrase, blocks Aβ fibril formation and suppresses dengue virus proliferation. Rolitetracycline mediates the inhibition of Aβ fibrils via a specific three-dimensional pharmacophore conformation, and exerts bacteriostatic and bactericidal activities. Rolitetracycline acts synergistically with Penicillin G (HY-N7139) or Cephalothin (HY-B1275A) to alter the effects on microbial growth. Rolitetracycline serves as an important tool compound for the study of bacterial infections (urinary tract infections, sepsis), HIV-1 and dengue virus infections, as well as Alzheimer's disease.
    Rolitetracycline
  • HY-P991069
    VRC-01 1412901-55-3 99.805%
    VRC-01 is a broadly neutralizing IgG1 monoclonal antibody that targets HIV-1 envelope glycoprotein gp120 Protein. VRC-01 blocks HIV-1 viral entry by mimicking CD4 receptor interaction with HIV-1 gp120 and neutralizes broad HIV-1 clades. VRC-01 can be used for the research of HIV-1 infection.
    VRC-01
  • HY-182277
    GSK-1264 1392118-63-6
    GSK-1264 is an HIV-1 integrase inhibitor. GSK-1264 binds to a site spanning the HIV-1 integrase catalytic core domain and C-terminal domain, mediates formation of an open polymer of HIV-1 integrase dimers via inhibitor-bridged contacts between adjacent dimers. GSK-1264 disrupts late-stage HIV replication by interfering with viral particle assembly. GSK-1264 stimulates inappropriate polymerization of HIV-1 integrase. GSK-1264 can be used for the research of HIV infection.
    GSK-1264
  • HY-N18192
    Kuwanon L 88524-65-6
    Kuwanon L is an HIV-1 integrase (HIV-1 integrase) inhibitor, with IC50 values of 42 μM and 34 μM for LEDGF-dependent and LEDGF-independent integrase, respectively. Kuwanon L blocks the interaction between HIV-1 integrase and LEDGF/p75, with an IC50 of 22 μM. Kuwanon L inhibits HIV-1 replication in immune cells. Kuwanon L is applicable to research related to HIV-1 infection.
    Kuwanon L
  • HY-N16821
    Hydroxydihydrobovolide 1403940-81-7
    Hydroxydihydrobovolide is a α-β-unsaturatedγ-lactone found in Portulaca oleracea L.. Hydroxydihydrobovolide shows cytotoxicity against cancer cells and shows anti-HIV-1 activity (IC50 = 122.7 μM). Hydroxydihydrobovolide can be used for the researches of neuroblastoma and HIV-1 infection.
    Hydroxydihydrobovolide
  • HY-W012166
    N-Succinimidyl bromoacetate 42014-51-7 99.20%
    N-Succinimidyl bromoacetate (NHS-Bromoacetate) is a heterobifunctional crosslinking reagent, mainly used to modify the ɛ-amino group of lysine side chains. By covalently linking its bromoacetyl moiety to the ɛ-amino group of lysine in peptidomimetics, N-Succinimidyl bromoacetate enables their conjugation with thiol-modified nanoparticles via thioether bonds. N-Succinimidyl bromoacetate also performs bromoacetylation modification on carrier proteins, which then forms stable thioether bonds with the thiol groups of cysteine in peptides, thus efficiently preparing soluble peptide-protein conjugates with high substitution ratios. N-Succinimidyl bromoacetate can be used to prepare activated Sepharose derivatives for affinity chromatography, protein affinity labeling reagents, and peptide-protein immunogen conjugates with non-immunogenic linkages. N-Succinimidyl bromoacetate is applicable to studies related to HIV-1 infection and glioblastoma multiforme.
    N-Succinimidyl bromoacetate
  • HY-D0976
    NF279 202983-32-2 98.5%
    NF279 is a selective P2X1 receptor antagonist and NTPDase inhibitor, with a P2X1 IC50 value of 19 nM. NF279 suppresses GABA-evoked currents, reduces ATP-excited respiratory activity, alters hypoglossal nerve burst parameters, and blocks CXCR4, CCR5, CXCR3, and CXCR7-mediated calcium responses. NF279 arrests HIV-1 fusion downstream of CD4 binding, inhibits R5- and X4-tropic HIV-1 strains. NF279 can be used for the research of HIV-1 infection.
    NF279
  • HY-142989
    1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine 99296-81-8 ≥98.0%
    1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is a polyunsaturated phospholipid that serves as a component of lipid monolayers and small unilamellar vesicles. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine can be used to prepare endoplasmic reticulum-targeted liposomes (PERLs), which are composed of 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, l-α-phosphatidylinositol and l-α-phosphatidylserine at a molar ratio of 1.5:1.5:1:1. PERLs reduce cholesterol levels in human peripheral blood mononuclear cells (PBMCs) and decrease HIV-1 particle secretion from HIV-1-infected PBMCs. Liposomes formed from 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine exhibit cytotoxicity against leukemia cells. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is applicable to studies related to hepatitis C virus infection, HIV infection, hepatitis B virus infection and leukemia.
    1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine
  • HY-P4076
    MPG peptides, Pβ 791642-10-9 98.26%
    MPG peptides, Pβ is an amphipathic cell-penetrating peptide. MPG peptides, Pβ consists of three components: the hydrophobic fusion sequence (GALFLGFLGAAGSTMGA) of HIV glycoprotein 41, a spacer domain (WSQP), and the nuclear localization signal (KKKRKV) of the large T antigen of Simian virus 40. MPG peptides, Pβ can form stable non-covalent complexes with nucleic acids (including DNA) through electrostatic interactions and improve their intracellular delivery. MPG peptides, Pβ can be used in studies of HIV-1-related immune responses.
    MPG peptides, Pβ
  • HY-110354
    UCM05 1094451-90-7 99.22%
    UCM05 (G28UCM) is a fatty acid synthase (FASN) and filamentous temperature-sensitive protein Z (Ftsz) inhibitor. UCM05 inhibits fatty acid synthesis, viral replication, and Gram-positive bacterial growth. UCM05 binds to FtsZ GTP-binding sites, inhibits GTPase activity, and disrupts Z-ring localization. UCM05 can be used for the research of HSV-1/2 infection, HIV-1 infection, and Gram-positive bacterial infections[1][2][3].
    UCM05
  • HY-125183
    BMS-818251 2974489-09-1 99.36%
    BMS-818251 is a HIV-1 attachment and entry inhibitor. BMS-818251 binds to HIV-1 Env gp120, interferes with viral attachment and entry processes, and inhibits HIV-1 viral replication. BMS-818251 can be used in studies related to HIV-1 infection.
    BMS-818251
  • HY-P2988B
    Neuraminidase, arthrobacter ureafaciens 9001-67-6
    Neuraminidase, arthrobacter ureafaciens is a neuraminidase derived from Arthrobacter ureafaciens. Neuraminidase, arthrobacter ureafaciens catalyzes the removal of sialic acid residues from cell surfaces and viral glycoconjugates. Neuraminidase, arthrobacter ureafaciens enhances HIV-1-mediated syncytium formation and promotes the viral binding and entry steps in the HIV-1 replication cycle.
    Neuraminidase, arthrobacter ureafaciens
  • HY-162074
    Nipamovir 2651908-78-8 98.60%
    Nipamovir is an orally active anti-HIV prodrug. Nipamovir is cleaved in vivo by glutathione and other active thiols. Nipamovir inhibits the replication of HIV-1RF and HIV-192HT599 in cells, with EC50 values of 3.64 μM and 3.23 μM, respectively. Nipamovir can be used in studies related to HIV infection.
    Nipamovir
  • HY-157469
    TNT-i
    TNT-i (NPD3064) is an inhibitor targeting M-Sec. TNT-i inhibits M-Sec-induced tunneling nanotube (TNT) formation reversibly. TNT-i reduces wild-type HIV-1 production in macrophages and M-Sec-expressing T cells. TNT-i shows low cytotoxic effects on macrophages and T cells. TNT-i can be used for the research of HIV-1 infection.
    TNT-i
  • HY-164201
    HIV-1 inhibitor-69 257891-65-9 99.39%
    HIV-1 inhibitor-69 is an HIV-1 reverse transcriptase inhibitor. HIV-1 inhibitor-69 protects cells against HIV-1 infection. HIV-1 inhibitor-69 can be used for the research of acquired immunodeficiency syndrome (AIDS).
    HIV-1 inhibitor-69
  • HY-110354R
    UCM05 (Standard) 1094451-90-7
    UCM05 (Standard) is the analytical standard of Lysipressin. This product is intended for research and analytical applications. UCM05 (G28UCM) is a fatty acid synthase (FASN) and filamentous temperature-sensitive protein Z (Ftsz) inhibitor. UCM05 inhibits fatty acid synthesis, viral replication, and Gram-positive bacterial growth. UCM05 binds to FtsZ GTP-binding sites, inhibits GTPase activity, and disrupts Z-ring localization. UCM05 can be used for the research of HSV-1/2 infection, HIV-1 infection, and Gram-positive bacterial infections[1][2][3].
    UCM05 (Standard)
  • HY-P992351
    ELB021
    ELB021 is an antibody inhibitor targeting the CD160 checkpoint. ELB021 specifically binds to CD160 on the cell surface and blocks its immune checkpoint pathway, thereby stimulating innate and adaptive anti-tumor immune responses. ELB021 effectively eliminates CD160-expressing cancer cells by enhancing T cell proliferation and CD8+ T cell-mediated cytotoxicity. Independent of PD-1 regulation, ELB021 is applicable to research related to B-cell leukemia and HIV-1 infection.
    ELB021